Dianthus Therapeutics, Inc. - Common Stock DNTH 深 滬
等待開盤 11-05 09:30:00 美东时间
33.20
-0.830
-2.44%
華盛通- 最 高34.11
- 今 開33.89
- 成交量 36.41万股
- 最 低 32.96
- 昨 收 34.03
- 總市值 13.22亿
- 52周最高 40.16
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 13.365
- 委 比 93.48%
- 總股本 3980.44万
- 歷史最高 336.00
- 量 比 0.92
- 振 幅 3.38%
- 歷史最低 5.136
- 每 手 1
- 風險率 5.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dianthus Therapeutics Reviews New Data From Phase 2 MaGic Trial Of Claseprubart In Generalized Myasthenia Gravis Presented At AANEM Annual Meeting
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosingPhase 3 gMG trial planned
10-30 03:32
终于反攻！创新药四季度催化剂密集，港股通创新药ETF(159570)再度涨超1%，近20日“吸金”超13.6亿元！机构：看好创新药长期逻辑！
今日（10.24），受政策面影响市场情绪回暖，港药再度反攻。100%创新药含量的港股通创新药ETF（159570）涨超1%，盘中成交额快速突破8亿元！资金面上...
10-24 10:32
一天三个BD，创新药再掀狂潮！翰森制药逆市涨近4%，BD总额超15.3亿美元！港股通创新药ETF(159570)资金近20日净流入超29亿元！
今日（10.17），在连续两日反攻后，港股通创新药ETF（159570）回调一度超1%，现跌幅收窄至0.38%，盘中成交额快速突破8.6亿元！资金面上，近20日...
10-17 11:13
10亿美元出海，来自今年最火IPO之一
（来源：动脉新医药） 10月16日晚，南京维立志博与Dianthus Therapeutics宣布已就DNTH212（LBL-047）达成独家许可协议。双方达成...
10-17 08:00
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Dianthus Therapeutics and Nanjing Leads Biolabs have entered into an exclusive licensing agreement for DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL to reduce Type 1 interferon production and suppress B cell function, respectively. DNTH212 has shown superior performance compared to existing therapies, with potential for improved outcomes in severe autoimmune diseases. The FDA has cleared the IND for DNTH212, and Phase 1 st...
10-16 11:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Truist Securities Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $56
Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $56.
10-14 21:07
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Dianthus Therapeutics announces Phase 2 MaGic trial results and new preclinical data for claseprubart, an active C1s inhibitor, in generalized Myasthenia Gravis (gMG) will be presented at the AANEM Annual Meeting on October 29, 2025. The company will also host a virtual forum discussing upstream targeting and MG treatment through C1s inhibition. Claseprubart, designed to selectively inhibit the classical complement pathway, may offer potential be...
10-02 12:00
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Clear Street Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $100
Clear Street analyst Bill Maughan initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $100.
09-17 21:45
